Introduction {#S0001}
============

Colon cancer, as one of the most common malignancies in the digestive gastrointestinal tract,[@CIT0001] accounts for one-third of the estimated new digestive cancer cases.[@CIT0002] For colon cancer, positive histological confirmation of American Joint Committee on Cancer (AJCC) stage is a significant indicator in managing the next therapeutic strategy.[@CIT0003] However, classification of N stage (namely lymph node metastasis status) depends on the resection range of surgical procedure and circumspective examination of pathologists, which may lead to inevitable bias and major error in evaluating merely the positivity of lymph node metastasis. The false-negative nodal staging caused by inadequacy of lymph node retrieval exists in AJCC stage I--III colon cancer on a broad scale.

Lymph node ratio (LNR), first reported by Berger in 2004,[@CIT0004] is defined as the number of positive lymph nodes (PLNs) divided by the total examined lymph nodes. LNR has been reported[@CIT0005]--[@CIT0008] many times to be a robust predictor of survival, better than traditional N stage; therefore, the specific clinical advantage of LNR with respect to non-TNM factors such as age, differentiation grade, has still not been explored in colon cancer patients with a population-based scale.[@CIT0009] Many reports have studied the clinical value of LNR by only focusing on stage III colon cancer (with lymph node metastasis) and demonstrated that LNR has no clinically prognostic power to differentiate Stage I and Stage II (colon cancer patients with no lymph node metastasis).[@CIT0010] However, according to the current AJCC classification on colon cancer, the same T categories with or without lymph node metastasis were considered as different prognosis groups, even in selective patients with a low value of LNR (such as 1 PLN of 99 examined lymph nodes). It may be assumed that such patients would be considered to have a preferable prognosis compared to non-lymph node metastasis patients. Thus, the specific prognostic stratification of these patients should be further reclassified.

Thus, in this study, we use data retrieved from a large Chinese center to identify good cutoff values of LNR affecting survival and to construct a modified stage for prognosis prediction in colon cancer patients with no distant metastasis. The capability of the constructed model was further determined through the validation of Surveillance, Epidemiology, and End Results (SEER) registry performed to determine the specific prognostic capability. In addition, a novel nomogram including LNR breaking through the traditional TNM system should be established to assist in chemotherapy risk stratification and survival predictor precisely.

Methods and materials {#S0002}
=====================

Patients and data resources {#S0002-S2001}
---------------------------

This study was approved by the ethics committee of Zhongshan Hospital, Fudan University, and informed written consent was obtained for each patient. For the primary cohort, the clinical data of 2,152 colon cancer patients without distant metastasis at Zhongshan Hospital between January 2008 and December 2013 were derived from the single-institutional database. Patients with colon adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma were included in this study. Patients with multiple primary cancer, preoperative adjuvant therapy and missing follow-up information were excluded ([Figure 1](#F0001){ref-type="fig"}). All cancers were described in the study according to the TNM Classification of Malignant Tumors, eighth edition (TNM 8th).Figure 1Flow diagram of stage I\\II\\III colon cancer patients enrolled from our institution and the SEER database.**Abbreviations:** LNR, lymph node ratio; SEER, surveillance, epidemiology, and end results.

For the validation cohort, data of patients with colon cancer (site code C18.2 -- Ascending colon, C18.3 -- Hepatic flexure of colon, C18.4 -- Transverse colon, C18.5 -- Splenic flexure of colon, C18.6 -- Descending colon, C18.7 -- Sigmoid colon and C18.8 -- Overlapping lesion of colon) diagnosed from 2004 to 2014 were retrieved from SEER database. The following International Classification of Diseases for oncology, third edition (ICD-O-3rd) histology codes were used to determine colon cancer: carcinoma (8010/3) and adenocarcinoma (8140/3). All the diagnoses were made through the positive histological examination, and data of unresectable patients were excluded. Other data containing age at diagnosis, sex, date of initial diagnosis, tumor differentiation, location of distant metastasis and cancer-specific survival (CSS) were retrieved from databases. For the evaluation of AJCC 8th edition TNM stage was performed basing on the following codes: collaborative stage (CS) tumor size 2004, CS metastases at DX 2004, CS lymph nodes 2004 and derived AJCC stage group (7th edition). Colon cancer patients with unknown characteristics or lacking survival information were excluded in our study. After the retrieval process, data of 122,227 colon cancer patients were retrieved from the SEER database; the re-evaluation of AJCC stage based on tumor size, distant metastases and lymph nodes metastasis. Of 122,227 patients, 77,406 colon cancer patients without distant metastasis were retrieved from the database.

Statistical analysis {#S0002-S2002}
--------------------

Statistical analyses were performed using the SPSS statistical package. The chi-squared test and Fishers exact test were used to compare proportions when appropriate, whereas means were compared using a nonparametric test. Pearson correlation and nonlinear exponential regression analysis were also carried out. Overall survival (OS) analyses were carried out using the Kaplan--Meier method, and the results were compared using a log-rank test. A multivariable Cox proportional hazards model predicting OS was performed using backward stepwise selection. Risk factors were expressed as \[HR, 95%CI\]. Statistical significance was defined as *P*-value less than 0.05. The cutoff value of the LNR was determined by the X-tile (3.6.1, Yale University) from the primary cohort patients with all ranges of LNR data. The predictive nomogram was formulated on the basis of a multivariate analysis using the package of rms in R version 3.3.0. The validation and discrimination of the nomogram were determined by the Harrell concordance index (C-index) as an index of model performance. Higher C-index values indicate better discrimination.

Results {#S0003}
=======

Clinicopathological characteristics of colon cancer cases {#S0003-S2001}
---------------------------------------------------------

The flow diagram of cohort selection is shown in [Figure 1](#F0001){ref-type="fig"}. For the primary cohort, 2,152 patients with stage I\\II\\III colon cancer were included ([Table 1](#T0001){ref-type="table"}). Approximately 33.69% of patients had a tumor located at the sigmoid colon. More than 90% of patients had poor and intermediate differentiated tumors. The median survival time was 50.0 months (5-year survival rate, 37.77%). The median follow-up period was 83.2 months (range 1.3--124.5 months). For the validation cohort, the clinical data of 122,224 colon cancer patients diagnosed with histologically confirmed colon cancer were retrieved from the SEER database from 2004 to 2014. In total, 77,406 patients with stage I\\II\\III colon cancer were included in this study, and the baseline characteristics are shown in [Table 1](#T0001){ref-type="table"}. The median age at the year of diagnosis was 68 (ranging from 11 to 85). The primary site of colon cancer was the sigmoid colon (38.89%). For the differentiation grade of the primary site, approximately 7.10%, 74.43%, 16.60% and 1.87% of colon cancer patients suffered from well, moderate, poor and nonneoplastic differentiations, respectively.Table 1Baseline clinical characteristicsCharacteristicsPrimary cohortValidation cohortNo.%No%**Age, years** ≥601,42566.21%55,50471.71% \<6062733.79%21,90228.29%**Gender** Males1,24757.95%39,36650.86% Females90542.05%38,04049.14%**Primary site** Sigmoid colon72533.69%30,10238.89% Ascending colon43220.07%19,98125.81% Transverse colon47822.21%10,19413.17% Descending colon2079.62%6,6568.60% Hepatic flexure of colon1476.83%5,3226.88% Splenic flexure of colon1024.74%3,8995.04% Overlapping lesion of colon612.83%1,2521.61%**Differentiation** Low grade1,30560.64%63,11381.53% High grade84739.36%14,29318.47%**AJCC stage** I42819.89%14,60518.87% IIA47822.21%27,54935.59% IIB28813.38%2,1002.71% IIC22110.27%2,1872.83% IIIA24511.38%2,5603.31% IIIB26512.31%18,41823.79% IIIC22710.54%9,98712.90%[^2]

Determination of the cutoff value of LNR {#S0003-S2002}
----------------------------------------

In the primary cohort, the median examined lymph node (ELN) was 13.8, ranging from 1 to 82. The median PLN was 2.0, ranging from 1 to 42. The median LNR (PLN/ELN) value was 0.12, ranging from 0 to 1. Xtile (Version 3.6.1) was used to identify a survival-dependent cutoff in LNR values such that the resulting subgroups had significantly different survival courses. After the analysis, the cutoff values of LNR were determined as 0.05 and 0.50 (details are shown in [Figure S1](#SF0001)). A score of ≥0.50 was taken as the cut-off for high LNR level (mN2), \<0.05 was regarded as the low LNR level (mN0); thus, the median LNR level was between 0.05 and 0.50 (mN1). For the validation cohort, the median ELN was 17.0 (from 1 to 99). The median PLN was 3.0, ranging from 1 to 98. The median LNR was 0.26, ranging from 0.01 to 1.00. The proportions of mN0, mN1, and mN2 were 54.45%, 25.24%, and 20.31%, respectively.

Prognostic comparison between the mN stage and the classic N stage {#S0003-S2003}
------------------------------------------------------------------

In the primary cohort, through the analysis of Kaplan--Meier curves, LNR values of different levels demonstrated varied duration of survivals (*P*\<0.001) compared with classic N stage in the primary cohort ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). The median duration of survival was 70.0 (mN0), 48.0 (mN1) and 10.0 (mN2) months, respectively. For validation, the cutoff value constructed based on our data showed a similar result, differentiating the survival outcomes in SEER colon cancer patients ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}, *P*\<0.001). The median survival was 44.0 (mN1), 43.0 (mN2) and 34.0 months (mN3), respectively. Comparing to the classic N stage (C-index: 0.578, 95%CI: 0.428--0.893), the C-index of the modified N stage (C-index: 0.701, 95%CI: 0.588--0.827) was statistically larger (0.701 versus 0.578, *P*\<0.001 in the primary cohort), which demonstrated a preferable performance for discrimination. Similar statistical results can also be determined in the validation cohort.Figure 2Kaplan--Meier overall survival curves for patients of stratified LNR levels (**A and C**) and survival outcomes of different classic N levels (**B and D**). *P*-values were determined by the log-rank test.**Abbreviation:** LNR, lymph node ratio.

Preferable C-index has been observed for LNR level compared to classic N stage. Based on these findings, we further wonder whether there is a difference in the duration of survival between patients without lymph node metastasis (N0) and 0\<LNR\<0.05. [Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"} shows that there is no difference in survival outcomes between the two groups in the primary and validation cohorts, demonstrating that selective patients with smaller values of LNR, even with lymph node metastasis, could have the same prognostic survival outcome as their N0 counterparts. In addition, [Figure 3C](#F0003){ref-type="fig"} and [D](#F0003){ref-type="fig"} demonstrated that in both primary and validation cohorts the patients with 0\<LNR\<0.05 still have better survival outcomes than mN1 and mN2 patients. Furthermore, we explore whether this staging system is applicable to patient selection of adjuvant chemotherapy. Chemotherapy status was also recorded. [Figure 4](#F0004){ref-type="fig"} demonstrates survival benefit for adjuvant chemotherapy in each mN stage in primary (A, B, and C) and validation (D, E, and F) cohort. From our analysis, adjuvant chemotherapy shows no survival benefit in mN0 patients, even in patients with positive LN metastasis (*P*\>0.05). In contrast, for mN1 and mN2 patients, patients receiving chemotherapy demonstrated a better survival outcome than their no chemotherapy counterpart.Figure 3Kaplan--Meier overall survival curves for patients between N0 and 0\<LNR\<0.05 in primary (**A**) and validation cohort (**B**). Survival curves among 0\<LNR\<0.05, mN1 and mN2 were also drawn in primary (**C**) and validation (**D**) cohort. *P*-values were determined by the log-rank test.**Abbreviation:**LNR, lymph node ratio.Figure 4In the primary cohort, the efficacy of postoperative adjuvant chemotherapy is shown for patients of (**A**) mN0, (**B**) mN1, and (**C**) mN2 stage in OS. In the validation cohort, the efficacy of postoperative adjuvant chemotherapy is shown for patients of (**D**) mN0, (**E**) mN1, and (**F**) mN2 stage in OS.**Abbreviations:** OS, overall survival; LNR, lymph node ratio.

Reclassification based on lymph node ratio and tumor stage {#S0003-S2004}
----------------------------------------------------------

As the AJCC 8th classification divides stage I\\II\\III colon cancer into seven subgroups, I, IIA, IIB, IIC, IIIA, IIIB and IIIC were regarded as the commonly used stage for years. To determine the modified classification for stage I, II and III colon cancer, using mN0, mN1, and mN2 to respectively replace N0, N1, and N2 in situ, we constructed a new stage based on LNR level and tumor category ([Table 2](#T0002){ref-type="table"}). The modified classification included mI, mIIA, mIIB, mIIC, mIIIA, mIIIB, and mIIIC. In the primary cohort, the proportion of mI, mIIA, mIIB, mIIC, mIIIA, mIIIB, and mIIIC was, respectively, 17.19%, 20.21%, 15.29%, 16.17%, 4.65%, 23.61%, and 2.88% ([Figure 5A](#F0005){ref-type="fig"} and [B](#F0005){ref-type="fig"}, *P*\<0.001), the performance of the novel stage was statistically better than the classic stage (C-index: 0.687 versus 0.605). SEER data were also retrieved into the classification to validate the newly proposed classification. The proportion of each stage was 18.36%, 38.05%, 22.4%, 4.96%, 0.84%, 3.45%, 33.54%, and 1.15%, respectively. [Figure 5C](#F0005){ref-type="fig"} and [D](#F0005){ref-type="fig"} provided the Kaplan--Meier analysis for the validation of the newly proposed classification with statistical significance (*P*\<0.001).Table 2The AJCC N staging definitions and our proposed modified lymph node staging definitions based on LNR for stage I\\II\\III colon cancer**AJCC N classificationModified lymph node classification based on LNR**N0: No regional lymph node metastasismN0: LNR was less than 0.05N1: 1 to 3 regional lymph nodes are positivemN1: LNR was between 0.05 to 0.50N2: 4 or more regional lymph nodes are positivemN2: LNR was larger than 0.50**AJCC 8**th **stage I\\II\\III classificationModified stage I\\II\\III classificationT stageN stageM stageT stagemLN stageM stageStageStage**IT1--T2N0M0mIT1-T2mN0M0IIAT3N0M0mIIAT3mN0M0IIBT4aN0M0mIIBT4amN0M0IICT4bN0M0mIICT4bmN0M0IIIAT1--T2N1M0mIIIAT1--T2mN1M0T1N2M0T1mN2M0IIIBT3--T4aN1M0mIIIBT3--T4amN1M0T1--T3N2M0T1--T3mN2M0IIICT3--T4aN2M0mIIICT3--T4amN2M0T4bN1-N2M0T4bmN1-2M0**AJCC 8^th^ stage I\\II\\III classificationModified stage I\\II\\III classificationCohort**PrimaryValidationPrimaryValidation**Stage**No%No%**mStage**No.%No%I42819.89%14,60518.87%mI37017.19%14,21418.36%IIA47822.21%27,54935.59%mIIA43520.21%29,45538.05%IIB28813.38%2,1002.71%mIIB32915.29%3,8374.96%IIC22110.27%2,1872.83%mIIC34816.17%6500.84%IIIA24511.38%2,5603.31%mIIIA1004.65%2,6703.45%IIIB26512.31%18,41823.79%mIIIB50823.61%25,69233.54%IIIC22710.54%9,98712.90%mIIIC622.88%8881.15%[^3] Figure 5Kaplan--Meier overall survival curves for patients of modified classification (**A and C**) and survival outcomes of different classic AJCC stage levels (**B and D**).**Abbreviation:** AJCC, american joint committee on cancer.

While the number of ELN and PLN can be affected by the experience of surgeons or pathologists, as well as the operative procedures, we further investigated the value of the proposed classification by using subgroup analysis. Since the SEER database did not provide us with information about the experience of pathologists or surgeons, we divided the patients into two subgroups according to the year of diagnosis (2004--2009 and 2010--2014), based on an assumption that surgeons or pathologists in the latter subgroup might be more experienced than those in the former subgroup. Through our analysis, the ELN in the latter period was statistically higher than the former period (median ELN 18 vs 14, *P*\<0.001). Based on the proposed classification above, survival curves were also constructed in different groups of diagnosis period. In patients diagnosed between 2004 and 2009, the LNR level and our proposed classification could stratify patients with different survival ([Figure S2A](#SF0002) and [B](#SF0002)). Furthermore, in patients diagnosed after 2010, similar results could also be obtained ([Figure S3A](#SF0003) and [B](#SF0003)).

Prognostic nomogram for OS prediction {#S0003-S2005}
-------------------------------------

Data of both primary and validation cohort patients were included in univariate and multivariate analyses to determine the prognosis-related factors, which is demonstrated in [Table 3](#T0003){ref-type="table"}. From the multivariable analysis of OS, tumor differentiation grade (*P*=0.001, HR=1.144; 95%CI: 1.112--1.659), modified stage (*P*=0.001, HR=1.078; 95%CI: 1.010--1.748), age level (*P*=0.000), chemotherapy status (*P*=0.002, HR=0.604; 95%CI: 0.442--0.899) were regarded as independent risk indicators for tumor OS.Table 3Characteristics of patients in stage I\\II\\III colon cancer patients: univariate and multivariate analysisCharacteristicsPatients (validation)Overall survivalPatients (primary)Overall survivalUniHR (95%CI)MultiHR (95%CI)UniHR (95%CI)MultiHR (95%CI)**Total**77,4062,152**Gender**0.4560.965 (0.953--1.086)NANA0.7970.712 (0.408--1.247)NANAMales39,3661,247Females38,040905**Age (years)**0.0010.947 (0.886--0.989)0.0000.534 (0.488--0.657 )0.0000.789 (0.768--0.818)0.0000.945 (0.712--0.936)≥6055,5041,425\<6021,902727**Differentiation**0.0001.201 (1.002--1.349)0.0001.160 (1.082--1.339 )0.0001.326 (1.132--1.645)0.0011.144 (1.112--1.659)Low grade63,1131,305High grade14,293847**Modified stage**0.00001.566 (1.528--1.605)0.00001.634 (1.563--1.676 )0.0011.406 (1.054--1.874)0.0011.078 (1.010--1.748)mI14,214370mIIA29,455435mIIB3,837329mIIC650348mIIIA2,670100mIIIB25,692508mIIIC88862**Chemotherapy**0.00000.525 (0.499--0.542)0.00000.488 (0.472--0.527)0.0170.410 (0.347--0.505)0.0200.604 (0.442--0.899)Yes24,218681No53,1881,471

To precisely predict the prognosis in those colon cancer patients including non-TNM risk factors, one accurate prognostic nomogram which integrated age levels, tumor grade, modified stage classification, and chemotherapy status was proposed by multivariate Cox regression models according to the primary set ([Figure S4](#SF0004)). The C-index for OS prediction with the formulated nomogram was 0.696 (95%CI: 0.672--0.738), which was higher than the C-index of the AJCC staging system (0.605; 95%CI: 0.485--1.223) in the whole cohort, as is shown in [Table 4](#T0004){ref-type="table"}. [Table 4](#T0004){ref-type="table"} demonstrates the specific C-index of each prognostic model in primary and validation cohort. The higher C-index, the better predictive accuracy for OS the system achieved. Therefore, the nomogram containing our proposed classification was formulated to predict survival with superior performance. The internal and external validation curves were constructed to validate the performance of the prognosis-prediction model. As shown in [Figure S5](#SF0005), the observed probability of 1-, 3-, and 5-year OS in the primary cohort and 1-, 3-, and 5-year OS in the validation cohort showed optimal consistency with the nomogram-predicted OS.Table 4Discriminatory capabilities of the classification system in primary and validation cohortVariablesPrimary cohortValidation cohortC-index95%CI*P*-valueC-index95%CI*P*-valueAJCC N stage0.5780.428--0.693Reference0.6010.528--0.676ReferencemLNR stage0.7010.588--0.827*P*\<0.0010.7250.621--0.832*P*\<0.001AJCC I\\II\\III classification0.6050.485--0.723Reference0.6400.502--0.749ReferenceModified I\\II\\III classification0.6870.526--0.832*P*\<0.0010.7150.649--0.868*P*\<0.001Nomogram0.6960.672--0.738NANANANA[^4]

Discussion {#S0004}
==========

Surgery remains the curative treatment of choice for colon cancer.[@CIT0011] However, prognosis in colon cancer is still based on pathological criteria including TNM staging, and LNR has been proposed to improve the prediction of outcomes.[@CIT0010] LNR is dependent on optimal retrieval of lymph nodes---ELN and is defined as the number of PLN divided by the total ELN.[@CIT0012] Traditionally, the number of PLN was considered as a determinant factor to determine N stage. Compared with PLN (N stage), LNR was more independent owing to specific resection range and is more suitable for the clinical analysis in every case.[@CIT0013] On the other hand, LNR reflects the number of dissected lymph nodes, which may minimize stage migration and consequently allow more accurate prediction of survival than using the number of metastatic lymph nodes alone.[@CIT0014] In addition, with the concept of TME being regarded as the preferred operation in colon cancer and the increase in experiences of surgeons and pathologists, the benefit of the recommended N stage should be further explored.

In many other kinds of tumor, LNR was found to be a prognostic factor in predicting the survival of patients.[@CIT0015]--[@CIT0017] In colon cancer, this factor was also well analyzed.[@CIT0018],[@CIT0019] It is also obvious that the number of LNR have no clinical value in Stage I and Stage II colon cancer patients with no lymph node metastasis. Previously, Ali[@CIT0018] reported that LNR is a more accurate prognostic factor than lymph node stage in stage III colon cancer patients; however, this study only included 66 patients and has a relatively low volume of the study group. Ramzi[@CIT0019] discussed the relationship between the LNR and the resection length, therefore, whether the prognostic classification was based on the ELN and LNR was less explored. Hirotoshi[@CIT0020] reported that adding the concept of LNR and location of lymph node metastasis to TNM staging could improve the accuracy of evaluating nodal status in colorectal cancer patients. However, this study included patients with rectal cancer, which had quite different operation standards compared with colon cancer. Mohan[@CIT0010] reported that N1/N2 and LNR do not provide additional prognostic value to current staging for OS, with an analysis of only 402 colon cancer patients in one center. Thus, all current research about LNR explored the value in stage III colon cancer. However, some patients with a lower value of LNR may have the same survival outcomes as the classic N0 (stage I and stage II) patients. Thus, on the one hand, when exploring the prognostic cutoff value of LNR, the factor of no lymph node metastasis should be adjusted, and value of proposed classification should be re-evaluated and validated by another large volume of colon cancer cases; on the other hand, as 0.05 was determined as a cutoff value for LNR, including the data of stage I and II patients can also have similar survival outcome compared with patients with 0\<LNR\<0.05, which can improve prognosis power for this cutoff value.

In this study, 2,152 and 77,406 cases with stage I\\II\\III colon cancer from one Chinese center and the SEER database were enrolled in the analysis. Through analysis of the clinical characteristics, three subgroups divided based on the cutoff LNR value (mN0, mN1, and mN2) were constructed and considered as the modified LNR stage. LNR levels had significant correlations with the duration of survival, as did age level, tumor grade, and T classification, which are generally consistent with a previous report.[@CIT0021] The mN stage demonstrated good performance for differentiating different various survival outcomes in both primary and validation cohort patients ([Figure 2](#F0002){ref-type="fig"}). Retrospectively, duration of survival between the patients without lymph node metastasis (N0) and 0\<LNR\<0.05 was compared, and the statistical difference was not observed in Kaplan--Meier analysis, as is shown in [Figure 3](#F0003){ref-type="fig"}, demonstrating that it is necessary to retrieve as many lymph nodes as possible during the operation. The mN stage can also be a predictive indicator for patients selection of adjuvant chemotherapy. Furthermore, [Table 2](#T0002){ref-type="table"} shows a modified classification based on LNR and classic AJCC T category in both cohorts. To evaluate the clinical value of this novel classification, the duration of survival demonstrated different survival outcomes in mI, mIIA, mIIB, mIIC, mIIIA, mIIIB, and mIIIC. From the results, we considered that the stage constructed based on LNR was prognostically preferable to the classic N stage. Classic N stage did help to inform the prognostic outcome and provide treatment reference in managing the colon cancer.[@CIT0002] However, because ELN and PLN are largely influenced by the experience of surgeons or pathologists, as well as the operative procedures, random conditions still exist that some patients with one lymph node metastasis may actually have more lymph nodes metastasis, while some patients who have only one metastasis after retrieving as many as 99 lymph nodes may be prognostically better than their 1 PLN counterpart. Thus, the LNR, as an independent value, can improve the power to determine these patients with better accuracy.

In addition to TNM factors, we also construct a prognostic nomogram containing our modified stage and non-TNM factors such as age level, tumor grade, and adjuvant chemotherapy status. The analysis demonstrated that our proposed model manifested superior predictive value compared to the TNM staging system alone. In addition, the formulated nomogram staging system revealed better performance in risk stratification for the prognosis of patients with resected colon cancer than TNM stage system with a better C-index. All these statistical results were verified in the internal and external validation cohort.

Our study has some limitations. First, since molecular examination results have already been added into the AJCC 8th stage system, several known molecular prognostic factors such as RAS and BRAF were not captured from the SEER database, which may lead to the lack of further analysis; the second limitation is the retrospective nature of this study. In order to confirm the prognosis predictive results, a large control trial may still be required. Additionally, the C-index of the nomogram is good but not excellent. Many other factors can also influence prognosis, and further research is still warranted to improve the accuracy of the nomogram. However, the size of the present study, which we believe to be the largest in stage I\\II\\III colon cancer, provides a comprehensive epidemiologic picture and a more accurate prognostic classification system.

In conclusion, lymphatic metastasis is very common in patients with colon cancer. In colon cancer patients without distant metastasis, LNR was preferable to classic N stage for discriminating survival outcomes and prediction of chemotherapy. Further, our newly proposed classification based on LNR and AJCC T category effectively demonstrated preferable risk stratification capability. Furthermore, a nomogram including the novel classification and non-TNM factors formulated in this study revealed better discrimination capability to predict 1-, 3- and 5-year OS rates.
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Figure S1A demonstration of the result from the analysis of X-tile. Figure S2SEER patients diagnosed between 2004 and 2009, (**A**) patients with LNR\>0.50 had significantly worse prognosis than patients with LNR\<0.05 and patients with LNR between 0.05 and 0.50 (*P*\<0.0001), and (**B**) survival analysis showed that modified stage mI, mIIA, mIIB, mIIC, mIIIA, mIIIB, and mIIIC had stratified survival (*p*\<0.0001).**Abbreviations:** LNR, lymph node ratio; SEER, Surveillance, Epidemiology, and End Results. Figure S3SEER patients diagnosed after 2010, (**A**) patients with LNR\>0.50 had significantly worse prognosis than patients with LNR\<0.05 and patients with LNR between 0.05 and 0.50 (*P*\<0.001), and (**B**) survival analysis showed that modified stage mI, mIIA, mIIB, mIIC, mIIIA, mIIIB, and mIIIC had stratified survival (*p*\<0.001).**Abbreviations:** LNR, lymph node ratio; SEER, Surveillance, Epidemiology, and End Results. Figure S4Nomogram to predict OS of patients with AJCC stage I\\II\\III colon cancer. To validate the nomogram, the sum of each predictor point was charted on the total points axis. The 1-, 3-, and 5-year OS rates were estimated by plotting a straight vertical line from the charted total points axis to the same OS rate axis. For the "Age level" line, 1 indicates "≥60 years" old and 0 indicates "\<60 years old". For the "Chemo" line, 1 refers to "adjuvant chemotherapy performed" and 0 refers to "not performed". For the "Grade" line, 0, 1, 2 and 3 refer to the well-differentiated, median-differentiated, poorly differentiated and undifferentiated, respectively. For the "modified stage" line, 1 to 7 separately refer to mI to mIIIC stage.**Abbreviations:** AJCC, American Joint Committee on Cancer; OS, overall survival. Figure S5Calibration curves for the nomogram. The calibration curves predict OS at 1 year (**A**), 3 years (**B**), and 5 years (**C**) in the primary cohort and at 1 year (**D**), 3 years (**E**) and 5 years (**F**) in the validation cohort.**Abbreviation:** OS, overall survival.
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